CAS: 1797983-09-5

Ethyl 3-((6-(4,5-Dihydro-1H-Benzo[D]Azepin-3(2H)-Yl)-2-(Pyridin-2-Yl)Pyrimidin-4-Yl)Amino)Propanoate Hydrochloride

GSK-J4 Hydrochloride

GSK J4 HCl is a small-molecule inhibitor, which is derived from synthetic chemistry methods, designed specifically to target the histone demethylase JMJD3/UTX. This compound functions by inhibiting the activity of the enzyme, effectively modulating epigenetic modifications through its influence on histone demethylation processes. The primary mode of action of GSK J4 HCl involves its ability to chelate the iron cofactor in the catalytic site of JMJD3/UTX, ultimately leading to the suppression of H3K27me3 demethylation. This results in altered gene expression patterns, affecting pathways that can further scientific understanding of epigenetic regulation in cellular differentiation and development. In research applications, GSK J4 HCl is utilized extensively to investigate the role of histone demethylases in various biological processes and diseases. It offers a valuable tool for probing the mechanistic aspects of transcriptional regulation and has potential implications in studying cancer biology, inflammation, and neurobiology, where aberrant epigenetic modifications play a crucial role. The compound aids in elucidating the function of epigenetic marks and contributes to the development of novel therapeutic strategies targeting epigenetic pathways.

GSK-J4 Hydrochloride (GSK J4 HCl) is a cell permeable, potent and selective histone demethylase(JMJD3 )inhibitor. It is an ethyl ester derivative of the GSK-J1.